Track topics on Twitter Track topics that are important to you
Foundation Medicine (NASDAQ: FMI) is a molecular information company focused on fundamentally changing the way patients with cancer are treated. Our proprietary molecular information platform generates actionable genomic information about a patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively. The Company’s first clinical product, FoundationOne™, is the first commercially available comprehensive molecular information product designed for use in the routine care of patients with cancer.
As the molecular drivers of cancer are better understood and more targeted therapies are developed against those drivers, there is an ever-growing need to perform comprehensive molecular analysis of tumors to determine the optimal treatment strategy for each patient. Foundation Medicine is pioneering the development of a comprehensive cancer diagnostic test that represents this critical step toward individualized cancer care by helping physicians recommend treatment options for each patient based on the molecular subtype of their cancer.
By utilizing next-generation sequencing on small amounts of cancer tissue, relevant genomic information that will help doctors make the most informed treatment recommendations will be captured in one test with greater than 99% sensitivity and specificity for alterations within all relevant cancer genes. Test results will be uniquely reported within the context of publicly available scientific and medical literature and clinical trials, integrating complex genomic research in a coordinated and easily accessible way for physicians to inform treatment recommendations.
One Kendall Square, Suite B3501
Roche has clearly seen significant potential in Foundation Medicine’s work in genomics to pay $2.4 billion to take complete ownership of the company. The big pharma company had already owned 58% of ...
The partnership will also enable Foundation Medicine to move into ex-US markets like Japan, where it is working with drugmake -More-
The partnership will also enable Foundation Medicine to move into ex-US markets like Japan, where it is working with drugmaker Chugai.
Roche, today announced it has acquire all of the outstanding shares in Foundation Medicine that is not already owned by Roche and its affiliates for $2.4B, representing $137 per share. Together, the c...
Roche this morning agreed to acquire the part of Foundation Medicine it didn’t already own, another big vote of confidence in the broad tumor profiling panels that have struggled to gain traction bu...
Roche is buying the shares it does not already own in US molecular information company Foundation Medicine (FMI), in a deal valued at $2.4 billion.
Roche bought a 56% stake in Foundation Medicine in 2015 for $1 billion and is purchasing the remainder of the company later t -More-
NewsNovartis and Foundation Medicine have announced a strategic collaboration allowing the development of companion diagnostic (CDx) tests.
ēsika 3-in-1 Pro Make Up Foundation SPF 20
Sheer Cover Mineral Foundation SPF-15
CPB Silky Cream Foundation I
cle de peau BEAUTE Cream Foundation I
SHISEIDO Perfect Refining Foundation
Ursula Ward, Chief Executive, Florence Nightingale Foundation, email@example.com , describes the role of the foundation and its plans for the future.
Shallow foundation is a common foundation type that is usually used for small to medium size structures. The bearing ability and the failure mechanism of shallow foundation are the fundamental concern...
This study compared a plant-based, olive oil diet to the diet recommended by the Prostate Cancer Foundation for weight loss and improvement in some laboratory biomarkers.
Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA (ctDNA) withi...
The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make ...
To evaluate the efficacy of Moxibustion in the treatment of Ulcerative Colitis, thus the scientific foundation for rational use of Moxibustion in clinical usage, in order to find admission...
This study evaluates the effectiveness of two online Lifestyle Medicine programs. Participants will be randomized by residence, urban vs. rural, into one of two Lifestyle Medicine programs...
The Medco Foundation was established with the generous support of Medco Health Solutions, Inc. The Foundation focuses on supporting activities aimed at educating and informing the general public about...
Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the gen...
The Foundation for Mitochondrial Medicine is a 501(c) (3) non-profit organization dedicated to supporting the development of the most promising research and treatments of the many...
Northwestern Medical Faculty Foundation, Inc. (the Foundation) is a premier, multi-specialty physician organization committed to providing high quality care to patients, and to supporting the research...
We have published hundreds of Foundation Medicine, Inc. news stories on BioPortfolio along with dozens of Foundation Medicine, Inc. Clinical Trials and PubMed Articles about Foundation Medicine, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Foundation Medicine, Inc. Companies in our database. You can also find out about relevant Foundation Medicine, Inc. Drugs and Medications on this site too.
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...